Statement: Zantac (Ranitidine) Litigation – Delaware Supreme Court to Review Superior Court's Daubert Decision
Statement: Zantac (Ranitidine) Litigation – Delaware Supreme Court to Review Superior Court's Daubert Decision
GSK plc (LSE/NYSE: GSK) welcomes today's decision by the Delaware Supreme Court that it will review the Delaware Superior Court's decision allowing the introduction of plaintiffs' expert evidence at trial. Interlocutory reviews are granted in exceptional circumstances, and GSK is pleased that the Supreme Court is of the view that such circumstances are present here.
GSk plc (LSE/NYSE: GSK)对特拉华州最高法院决定复审特拉华州高级法院允许在审判中引入原告专家证据的决定表示欢迎。特例情况下才会批准中间上诉,GSk很高兴看到最高法院认为此处存在这样的情况。
The scientific consensus remains that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer. Since 2019, there are 16 epidemiological studies looking at human data regarding the use of ranitidine, including outcomes for more than 1 million patients using ranitidine, supporting this consensus.
科学共识仍然是:没有一致的或可靠的证据表明雷尼替丁增加了任何癌症的风险。自2019年以来,已经有16项流行病学研究关注使用雷尼替丁的人类数据,包括超过100万使用雷尼替丁的患者的结果,支持这一共识。
GSK is committed to vigorously defending itself and managing this litigation in the best interests of the Company and its shareholders. The Delaware litigation will progress in parallel with the Delaware Supreme Court review. Alongside review by the Delaware Supreme Court, the Company will press additional defenses in the litigation, including failure to provide proof of use and proof of diagnosis requirements recently ordered by the Court.
GSk致力于积极捍卫自己,并在公司和股东的最佳利益下管理此诉讼。特拉华州的诉讼将与特拉华州最高法院审查同时进行。除了特拉华州最高法院的审查外,公司还将在诉讼中提出其他辩护措施,包括法院最近下令提供使用证明和诊断证明的要求。
Notes to Editors
爱立信的5G网络基础设施产品组合包括
* The Daubert standard, established in the U.S. Supreme Court case Daubert v. Merrell Dow Pharmaceuticals, Inc. 509 US 579 (1993) provides criteria for evaluating whether expert testimony is admissible under Federal Rule of Evidence 702. Under Rule 702 and Daubert, an expert may offer testimony if he or she is qualified by knowledge, education, training or experience in a given area and the testimony offered is reliable, relevant and helpful to the jury. In applying the Daubert standard, the Court acts as a gatekeeper, ensuring that expert opinions meet certain standards for reliability and that speculative or unreliable opinions are not presented to the jury. In Daubert, the Supreme Court identified four factors to guide assessment of an expert's methodology: (1) whether the expert's methodology has been tested or is capable of being tested; (2) whether the theory or technique used by the expert has been subjected to peer review and publication; (3) whether there is a known or potential error rate of the methodology; and (4) whether the technique has been generally accepted in the relevant scientific community. The Daubert standard is applicable to expert testimony in all federal cases. Many states also have adopted standards identical to the federal Daubert standard.
* Daubert标准是由美国最高法院案例Daubert v. Merrell Dow Pharmaceuticals, Inc. 509 US 579 (1993)确立的,它为评估专家证词是否符合联邦证据规则702的要求提供了标准。根据规则702和Daubert标准,只有具备在某一特定领域的知识、教育、培训或经验的专家可以提供证词,并且提供的证词必须是可靠的、相关的且对陪审团有帮助的。在应用Daubert标准时,法院充当守门人的角色,确保专家意见符合某些可靠性标准,并且不会向陪审团呈现投机或不可靠的意见。在Daubert案中,最高法院确定了指导评估专家方法的四个因素:(1)专家方法是否经过测试或可进行测试;(2)专家使用的理论或技术是否经过同行评议和发表;(3)方法的已知或潜在错误率是否存在;和(4)该技术是否在相关科学社区中被普遍接受。 Daubert标准适用于所有联邦案件中的专家证词。许多州还采用了与联邦Daubert标准相同的标准。
The term "Daubert Standard" comes from the United States Supreme Court case: Daubert v Merrell Dow Pharmaceuticals Inc 509 US 579 (1993).
道贝特标准一词来自于美国最高法院的案件:道贝特诉梅瑞尔多公司509美国579(1993)。
About GSK
关于GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
GSK是一家全球生物医药公司,其目的是通过联合科学、技术和才华于疾病之前获得优势。详情请访问gsk.com。
Cautionary statement regarding forward-looking statements
关于前瞻性声明的警告声明
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2023, and GSK's Q2 Results for 2024.
GSk 提示投资者,GSk 在本公告中发表的任何前瞻性声明或预测都存在风险和不确定性,可能导致实际结果与预期结果有所不同。 这些因素包括但不限于 GSK 的 2023 年年度报告表格 20-F 的第 3.D 条“风险因素”和 2024 年第二季度业绩。